CRVS

Corvus Pharmaceuticals, Inc.

2.40 USD
+0.04 (+1.69%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Corvus Pharmaceuticals, Inc. stock is up 12.15% since 30 days ago. The next earnings date is Mar 26, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 37.5% of the previous 7 February’s closed higher than January.

About Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc. focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company was incorporated in 2014 and is based in Burlingame, California.